Can naltrexone be used to treat binge‑eating disorder in adults, and what are the recommended starting dose, titration schedule, contraindications, and monitoring parameters?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: March 23, 2026 • View editorial policy

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.

Ask Question

Naltrexone for Binge Eating Disorder

Naltrexone is not a first-line or recommended treatment for binge eating disorder according to current evidence-based guidelines; psychotherapy (CBT or IPT) should be initiated first, followed by lisdexamfetamine or topiramate if pharmacotherapy is needed. 1

Treatment Algorithm for Binge Eating Disorder

First-Line Treatment

  • Eating-disorder-focused psychotherapy is the initial treatment (American Psychiatric Association Level 1C recommendation), delivered as individual or group therapy. 1
  • Cognitive-behavioral therapy (CBT) has the strongest evidence with large effect sizes for reducing binge episodes. 1
  • Interpersonal therapy (IPT) is an equally valid alternative targeting emotional triggers and relationships. 1

When to Consider Pharmacotherapy

  • Add medication only after 6 weeks of minimal or no response to psychotherapy, or if the patient explicitly prefers medication. 1

Medication Hierarchy (Not Including Naltrexone)

  1. Lisdexamfetamine – strongest pharmacologic evidence (RR = 2.61 for binge reduction; ~5 kg weight loss). 1
  2. Topiramate – comparable efficacy to lisdexamfetamine for binge reduction (MD -1.63) with greatest weight loss (~5.5 kg). 2
  3. SSRIs/SGAs – modest benefit for binge abstinence (RR = 1.67) but no significant weight loss; appropriate when comorbid depression/anxiety exists. 1

Naltrexone: Evidence and Limitations

Why Naltrexone Is Not Guideline-Recommended

  • The 2026 American Psychiatric Association guideline does not include naltrexone in its treatment algorithm for binge eating disorder. 1
  • The most recent network meta-analysis (2026) found naltrexone/bupropion combination did not significantly reduce binge frequency (MD -2.07,95% CI: -4.45 to 0.31). 2
  • A 2025 meta-analysis showed naltrexone/bupropion produced weight loss but insufficient evidence for binge eating reduction. 3

Supporting Evidence for Naltrexone

  • A 2025 meta-analysis of opioid antagonists (primarily naltrexone) showed moderate reduction in binge frequency (SMD = -0.624) and body weight percentage (SMD = -0.981), with dosage serving as a moderator. 4
  • Older studies (1988-1995) suggested high-dose naltrexone (200-300 mg/day) may reduce binge eating, while standard doses (50-100 mg/day) showed no significant effect. 5
  • A 2019 case series in adolescents reported 67% positive response to naltrexone for reducing purging/binge urges, though this was uncontrolled. 6

Critical Dosing Issue

  • FDA-approved dosing for naltrexone is 50 mg/day for alcohol dependence and 25-50 mg/day for opioid dependence. 7
  • Studies showing efficacy in binge eating used off-label high doses (100-300 mg/day), which carry higher risk of hepatocellular injury. 7, 5
  • The FDA label explicitly warns that single doses above 50 mg increase hepatotoxicity risk. 7

If Naltrexone Is Considered (Off-Label)

Contraindications

  • Current opioid use or dependence – naltrexone will precipitate severe withdrawal. 7
  • Patients must be opioid-free for 7-10 days (short-acting opioids) or up to 2 weeks (buprenorphine/methadone). 7
  • Acute hepatitis or liver failure – naltrexone is hepatotoxic. 7
  • Positive naloxone challenge test. 7

Dosing (Based on Research, Not FDA-Approved for BED)

  • Starting dose: 25 mg daily for opioid dependence protocol; 50 mg daily for alcohol dependence protocol. 7
  • Titration: Studies showing efficacy in binge eating used 100-300 mg/day, but this is off-label and carries hepatotoxicity risk. 5, 4
  • Practical approach: If attempting naltrexone, start at 50 mg daily and assess response before considering higher doses, balancing risks versus benefits. 7

Monitoring Parameters

  • Baseline assessment: Comprehensive metabolic panel, complete blood count, liver function tests (AST, ALT, bilirubin), renal function. 1
  • Ongoing monitoring: Liver function tests during treatment, especially if using doses >50 mg/day. 7, 6
  • Clinical monitoring: Binge eating frequency, weight, vital signs, mood symptoms. 1, 6
  • Opioid screening: Urine drug screen before initiation; consider naloxone challenge if occult opioid use suspected. 7

Common Adverse Effects

  • Nausea (9% in adolescent case series). 6
  • Gastrointestinal upset, headache, dizziness. 7
  • All liver function tests remained normal in monitored patients. 6

Clinical Bottom Line

Do not use naltrexone as first-line treatment for binge eating disorder. Start with CBT or IPT; if pharmacotherapy is needed after 6 weeks of inadequate response, choose lisdexamfetamine or topiramate based on the evidence hierarchy. 1, 2 Naltrexone lacks guideline support and has inconsistent evidence, with the combination naltrexone/bupropion showing no significant binge reduction in the highest-quality 2026 network meta-analysis. 2 If naltrexone is attempted off-label, use comprehensive monitoring for hepatotoxicity and ensure complete opioid abstinence before initiation. 7

References

1
Guideline

Evidence‑Based Management of Binge Eating Disorder

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2026

6
Research

Naltrexone Reduces Binge Eating and Purging in Adolescents in an Eating Disorder Program.

Journal of child and adolescent psychopharmacology, 2019

Related Questions

What are the typical dosing regimens of naltrexone for binge‑eating disorder?
Can a patient with binge‑eating disorder who does not engage in restriction, vomiting, laxative use, or other purging behaviors safely take bupropion (Wellbutrin)?
Can I add topiramate to my current regimen (methylphenidate, mirtazapine, buspirone, lamotrigine) to help with binge eating?
Is bupropion appropriate for treating binge‑eating disorder in adults, and what are the recommended dosing, contraindications, and monitoring parameters?
What are the recommended first‑line medications for binge‑eating disorder, including dosing, contraindications, and alternative pharmacologic options?
How effective are gelatin capsules in promoting nail growth?
What does a BUN-to-creatinine ratio of 25 indicate?
In colon adenocarcinoma, when is immunotherapy indicated and what regimens are recommended?
Should a repeat kidney biopsy be performed in a 45-year-old man with IgA nephropathy who has relapsed with increased serum creatinine and proteinuria while on optimal supportive therapy?
Does Tessalon (benzonatate) cause an increase in blood pressure?
For recurrent HSV prophylaxis, should acyclovir 800 mg twice daily be continued/extended as suppressive therapy?

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.